Plain-English translation of NCT04282031 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 1/2 β A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new experimental medication called to see if it's safe and works well for people with advanced cancers. The study has two main phases: first, researchers will test different doses of alone in people with various advanced solid tumors to find the best dose; then, they'll test this medication combined with existing breast cancer treatments in people with a specific type of advanced breast cancer.
Current treatments for advanced cancers don't always work well enough or patients may stop responding to them over time. Researchers are testing this new medication to see if it could offer another option, either on its own or alongside existing therapies, to help people with advanced cancers live longer and better.
Participants will visit a clinic regularly to receive the medication and have blood tests and scans to monitor how their cancer responds and how their body tolerates the treatment. In the first phase, participants will start with a single dose of the medication, then after a washout period, take it daily for 3 weeks followed by 1 week off (in 28-day cycles), with doctors watching for side effects. In the second phase for breast cancer, participants will take the new medication combined with one of two existing breast cancer drugs, either on a 3-weeks-on/1-week-off schedule or continuously for 28 days at a time, continuing until the cancer progresses or side effects become too difficult to manage.
AI-generated summary from trial data Β· Jun 27, 2026 Β· Not medical advice
China